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Figure 1. Spectrum of morphology in sclerotic cGVHD. A: Lichen sclerosus like disease with profound dyspigmentation in patient 3. B: Myofascial disease in patient 9.
C: Penile lichen sclerosus in patient 7. D. Dermal sclerotic plaques with “choke-hold” distribution in Patient 4. E and F: Bound down sclerosis of toes and guttate
sclerotic papules and plaques in patient 8.
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Skin involvement has been shown to be predictive of poor
prognosis in patients with chronic graft-versus-host disease
(cGVHD). However, cGVHD of the skin has not been well
described in children. The purpose of this study was to
characterize distribution, type, and extent of skin cGVHD and
correlate ﬁndings with laboratory markers, severity of dis-
ease, and multi-organ involvement in a cohort of pediatric
hematopoietic stem cell transplant recipients. 12 consecutiveFigure 2. Preceding edema was noted in 6 of 9 patients with spediatric patients with skin cGVHD seen at Dana-Farber
Cancer Institute and Boston Children’s Hospital were evalu-
ated over a 2-year period. 6 (50%) patients had de novo, 4 had
progressive, and 2 had quiescent onset cGVHD. Type of skin
GVHD included sclerotic (9), eczematous (2), and ichthyosi-
form (1). 8 of 9 (89%) patients with sclerotic cGVHD had
multi-organ involvement; 1 of 3 (33%) patients with non-
sclerotic disease had multi-organ involvement. All patients
with sclerotic cGVHD had steroid resistant disease while all
patients with non-sclerotic cGVHD responded either to
topical therapy or prednisone alone. Peripheral eosinophil
counts > 300 cells/uL was identiﬁed in 10 patients prior to
onset of cGVHD, of whom only one could be attributed to
drug hypersensitivity. Mean peak peripheral eosinophil
count of those with myofascial sclerotic cGVHD was sig-
niﬁcantly higher than that of remaining patients (1962 cells/
uL vs. 525 cells/uL, p¼0.03). Mean time of onset of eosino-
philia for patients with myofascial sclerotic cGVHD was
79 days (range 21-182) prior to onset of cGVHD. 6 patients
were noted to have otherwise unexplained edema of theclerotic cGVHD. Clockwise from left upper: Patient 9,9,7.
Figure 3. Ptyerygium inversum unguis in 4 participants with severe cGVHD characterized by sclerotic involvement and lung disease. Clockwise from left upper:
Patient 7, 3, 4, 12.
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with myofascial sclerotic cGVHD were signiﬁcantly more
likely than those with other types of skin cGVHD to have
preceding peripheral edema (6/6 vs. 0/4, p¼0.005). In addi-
tion, patients with severe cGVHD were signiﬁcantly more
likely than those with mild or moderate cGVHD to have
preceding peripheral edema (5/5 vs. 1/5, p¼0.05). Nail dys-
trophy was present in 7/12 (58%) patients in our cohort, and
was signiﬁcantly more likely to occur in patients with myo-
fascial sclerotic cGVHD than those with other forms of skin
cGVHD (7/7 vs. 1/5, p¼0.01). Pterygium inversum inguis, a
speciﬁc form of nail dystrophy, was present in 4 of 12 pa-
tients, and was signiﬁcantly more likely to occur in patients
awaiting lung transplantation (3/4 vs. 0/8, p¼0.02). This
study represents the largest cohort of pediatric patients with
skin cGVHD reported in the literature and suggests that pe-
ripheral eosinophilia, edema, and nail dystrophy are har-
bingers of severe cGVHD of the skin in children.251
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Background: While it has been noted clinically that the
mean corpuscular volume (MCV) for HSCT recipients may
tend to increase over time, literature describing changes to
mean corpuscular volume (MCV) following pediatric HSCT is
very limited. Macrocytosis is of clinical interest because it
may signal underlying bone marrow dysfunction. Conse-
quently, understanding the natural course of changes in the
MCV over time is important.Methods: We conducted a retrospective chart review of all
pediatric patients undergoing allogeneic (allo) or autologous
(auto) HSCT at the Medical University of South Carolina
during July 1, 2007-June 30, 2012 who have survived for >1
year after transplant without relapse. The sample included
16 auto-HSCT patients (10 patients with incomplete data)
and 32 allo-HSCT patients. Baseline MCV values were
recorded both at baseline (PBSC collection date for auto pa-
tients, HSCT admission date for allo patients) and at speciﬁc
intervals post-HSCT. Data was analyzed to identify the
presence of macrocytosis based on age-speciﬁc normal
values, the trend of MCV changes with time, and the time of
maximum change in MCV. Linear regression was used to
evaluate associations between factors and MCV changes.
Statistical signiﬁcance was accepted at P<0.05.
Results: Macrocytosis was present at baseline in 19% of the
allo patients and 0% of the auto patients. Maximum mean
MCV change for allo and auto patients was at 90 days post-
HSCT. At day 90, allo patients had a mean increase in MCV of
5.77 ﬂ (95% CI 2.77- 8.77), and auto patients had a mean
increase in MCV of 8.33 ﬂ (95% CI 2.80-13.87). For allo pa-
tients, 56%, 32%, and 40% were macrocytic at days 90, 365,
and 730 post-HSCT. For auto patients, 67%, 40%, and 40%
were macrocytic at days 90, 365, and 730 post-HSCT. For allo
patients, MCV changes were associated with ABO in-
compatibility (p¼0.043) but not with age, sex, diagnosis,
disease status at HSCT, prep regimen, graft source, cell dose,
GVHD, neutrophil engraftment, or platelet engraftment.
Compared to patients with no ABO incompatibility, the mean
change in MCV at day 90 was 14.38 ﬂ less for patients with
minor ABO incompatibility but was not signiﬁcantly different
for patients with major ABO incompatibility. For auto pa-
tients, MCV changes had a positive association with
neutrophil engraftment (p¼0.049) with a trend towards an
association with cell dose (p¼0.071) but not with age, sex,
diagnosis, initial chemotherapy, disease status at HSCT, prep
regimen, or platelet engraftment. For each additional day
increase in neutrophil engraftment, themean change inMCV
at day 90 is expected to increase by 1.91 ﬂ.
